IPP Bureau
Dr. Reddy's Laboratories launches Versavo in the UK
By IPP Bureau - March 19, 2024
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Sun Pharmaceuticals receives approval for Winlevi in Australia
By IPP Bureau - March 19, 2024
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
Zydus receives USFDA approval for Finasteride and Tadalafil capsules
By IPP Bureau - March 18, 2024
The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ II, India
AstraZeneca to acquire Amolyt Pharma
By IPP Bureau - March 18, 2024
Acquisition to further expand the Alexion, AstraZeneca Rare Disease pipeline beyond complement inhibition
Lupin appoints Christoph Funke as Chief Technical Operations Officer
By IPP Bureau - March 18, 2024
Christoph Funke's extensive career includes leadership roles at organizations such as Fresenius Kabi and Strides Pharma Science
Eris Lifesciences buys India formulation business of Biocon Biologics for Rs. 1,242 Cr
By IPP Bureau - March 17, 2024
Both organisations enter into a long- term collaboration to expand patient access in India
Syngene biologics facility to be operational for US, European customers from mid-year
By IPP Bureau - March 17, 2024
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
Cipla appoints Venkata Sai Mungara as Global Head – Supply Chain
By IPP Bureau - March 17, 2024
Mungara has over 25+ years of experience in the supply chain domain
Sumitomo Pharma announces availability of ORGOVYX in Canada
By IPP Bureau - March 17, 2024
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
Evonik Vland Biotech JV commences operations
By IPP Bureau - March 16, 2024
Grand opening of the joint venture between Evonik China and Shandong Vland Biotech in Qingdao, China
Evonik makes five generations healthier with EUDRAGIT coatings for targeted drug delivery
By IPP Bureau - March 16, 2024
More than 10,000 scientific publications containing EUDRAGIT
Bayer and Aignostics to collaborate on next generation precision oncology
By IPP Bureau - March 16, 2024
Strategic multi-year research collaboration to identify novel targets with strong disease links and to accelerate clinical development
Lupin receives Form 483 with 1 observation from USFDA after inspection at Aurangabad facility
By IPP Bureau - March 16, 2024
The company is confident of addressing the concern raised by the USFDA
Indranil Sen, CFO, Biocon resigned
By IPP Bureau - March 16, 2024
Sen spent a decade with Biocon and held various key roles,
